Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anticancer antibodies - ARCA biopharma

Drug Profile

Research programme: anticancer antibodies - ARCA biopharma

Alternative Names: IREM-1-antagonists; NTB-A; NTB-A-antagonists; NU 10458; NU 2444; NUVO 13759; NUVO 14453; NUVO 16587; NUVO 17289; NUVO 18778; NUVO 18832; NUVO 2788

Latest Information Update: 04 Oct 2012

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator
  • Developer ARCA biopharma Inc
  • Class Monoclonal antibodies
  • Mechanism of Action C-type lectin-like molecule-1 protein inhibitors; CD150 antigen inhibitors; CD300LF protein antagonists; Complement activation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Leukaemia

Most Recent Events

  • 04 Oct 2012 Discontinued - Preclinical for Leukaemia in USA (Parenteral)
  • 28 Jan 2009 Nuvelo has merged with ARCA biopharma to form ARCA biopharma Inc
  • 28 Aug 2003 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top